Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Boston Scientific (BSX) and Hologic (HOLX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKSResearch Report), Boston Scientific (BSXResearch Report) and Hologic (HOLXResearch Report).

Alkermes (ALKS)

In a report released today, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes, with a price target of $27.00. The company’s shares closed last Wednesday at $30.38.

According to TipRanks.com, Goodman has 0 stars on 0-5 stars ranking scale with an average return of -2.8% and a 41.3% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

Currently, the analyst consensus on Alkermes is a Moderate Buy with an average price target of $30.50, a -0.6% downside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $27.00 price target.

See the top stocks recommended by analysts >>

Boston Scientific (BSX)

In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Boston Scientific, with a price target of $50.00. The company’s shares closed last Wednesday at $43.06.

According to TipRanks.com, Bedford is a 5-star analyst with an average return of 13.1% and a 67.6% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Baxter International, and Edwards Lifesciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $50.17 average price target, a 15.2% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $50.00 price target.

Hologic (HOLX)

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic today and set a price target of $82.00. The company’s shares closed last Wednesday at $70.84.

According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -11.8% and a 33.1% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $81.44, representing a 15.5% upside. In a report released yesterday, BTIG also assigned a Buy rating to the stock with a $79.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALKS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed